These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3991529)

  • 1. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH)3.
    Fournier A; Demontis R; Tahiri Y; Herve M; Moriniere P; Leflon A; Abdull-Massih Z; Atik H; Benelmouffok S
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():390-4. PubMed ID: 3991529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3.
    Demontis R; Leflon A; Fournier A; Tahiri Y; Herve M; Moriniere P; Abdull-Massih Z; Atik H; Belbrik S; Renaud H
    Clin Nephrol; 1986 Sep; 26(3):146-9. PubMed ID: 3769230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indirect evaluation of the effect of 1 alpha-hydroxyvitamin D3 on intestinal absorption of aluminum].
    Demontis R; Reissi D; Noël C; Morinière P; Renaud H; Leflon P; Westeel PF; Brasseur J; Coevoet B; Fournier A
    Nephrologie; 1988; 9(3):135-8. PubMed ID: 3194044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3.
    Demontis R; Westeel PF; Boudalliez B; Moriniere P; Leflon A; Abdulmassih Z; Atik H; Renaud H; Fournier A
    Kidney Int Suppl; 1988 Mar; 24():S175-7. PubMed ID: 3163043
    [No Abstract]   [Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum.
    Demontis R; Reissi D; Noel C; Boudailliez B; Westeel PF; Leflon P; Brasseur J; Coevoet B; Fournier A
    Clin Nephrol; 1989 Mar; 31(3):123-7. PubMed ID: 2706809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
    Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interaction between active metabolites of vitamin D3 and blood aluminum in chronic uremic patients on dialysis].
    Panico F; Salvati A; Scoppa F; Testa GF; Capobianco A; Pacia S; Lauriello F; Aquino A; Tedesco V; Taccone W
    Minerva Urol Nefrol; 1993 Jun; 45(2):47-8. PubMed ID: 8235931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalacia.
    Fournier A; Fohrer P; Leflon P; Moriniere P; Tolani M; Lambrey G; Demontis R; Sebert JL; Van Devyver F; Debroe M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():371-6. PubMed ID: 3991525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aluminum-balance during haemodialysis (author's transl)].
    Graf H; Stummvoll HK; Kovarik J; Meisinger V; Wolf A; Pinggera WF
    Wien Klin Wochenschr; 1980; 92(11):391-4. PubMed ID: 7424016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
    Moriniere P; Roussel A; Tahiri Y; de Fremont JF; Maurel G; Jaudon MC; Gueris J; Fournier A
    Proc Eur Dial Transplant Assoc; 1983; 19():784-7. PubMed ID: 6878265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
    Brandi L; Egfjord M; Olgaard K
    Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of aluminium hydroxide intake on haemoglobin concentrations and blood transfusion requirements in haemodialysis patients.
    Cannata JB; Ruiz Alegria P; Cuesta MV; Herrera J; Peral V
    Proc Eur Dial Transplant Assoc; 1983; 20():719-24. PubMed ID: 6657691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.